Home

JOHN F THERO

CIK 1199637 · President and CEO · last filed 2024-02-12

JOHN F THERO is a President and CEO who has filed 84 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider exercised options covering $21.7K of CYT on Feb 12, 2024. Across all open-market trades the lifetime net is −$42.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.20M

Companies

6

Total Filings

84

Lifetime Open-Market Net

-$42.43M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Cyteir Therapeutics, Inc. (CYT) Delisted Director 22,828 $3.02 $68.9K $20.0K 4 2024-02-12
CinCor Pharma, Inc. (CINC) Delisted Director — $29.06 — $0 1 2023-02-24
CHIASMA, INC (CHMA) Delisted Director — $3.76 — $0 7 2021-08-05
AMRN President and CEO 162,157 $13.55 $2.20M -$42.45M 69 2021-08-03
ACUSPHERE INC (ACUS) Delisted Senior VP/CFO 91,504 — — $0 2 2007-09-06
VIACELL INC (VIAC) Delisted Sr.VP, Chief Financial Officer — $29.58 — $0 1 2007-07-02

Recent Filings

84 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-02-12 Cyteir Therapeutics, Inc. (CYT) Delisted Exer (M) +12,828 $21.7K EDGAR
2023-02-24 CinCor Pharma, Inc. (CINC) Delisted Disp (D) — $0 EDGAR
2023-02-07 Cyteir Therapeutics, Inc. (CYT) Delisted Grant (A) — $0 EDGAR
2022-05-12 Cyteir Therapeutics, Inc. (CYT) Delisted Buy (P) +10,000 $20.0K EDGAR
2022-02-07 Cyteir Therapeutics, Inc. (CYT) Delisted Grant (A) — $0 EDGAR
2021-08-05 CHIASMA, INC (CHMA) Delisted Disp (D) — $0 EDGAR
2021-08-03 AMRN Mixed +16,340 -$43.9K EDGAR
2021-07-02 AMRN Mixed +16,340 -$47.5K EDGAR
2021-05-28 AMRN Mixed +16,340 -$48.1K EDGAR
2021-04-30 AMRN Mixed +16,340 -$55.6K EDGAR
Showing 1–10 of 84
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.